Annexon to present Phase 2 ARCHER data on ANX007

Annexon announced the Company will present analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy at the Retina Society’s 57th annual scientific meeting being held September 11-15 in Lisbon, Portugal, and at the 24th annual Euretina Congress being held September 19-22 in Barcelona, Spain. ANX007 is a first-in-kind, non-pegylated antigen-binding fragment designed to block C1q locally in the eye with an intravitreal formulation. “The randomized ARCHER data for ANX007 in GA demonstrated broad-based protection of vision in standard and low light conditions, along with significant protection of visual structures in key regions of the eye important to visual acuity. Based on these data, we have initiated a Phase 3 pivotal ARCHER II trial to further evaluate the potential of ANX007 to be the first treatment to protect vision in GA,” said Douglas Love, president and chief executive officer of Annexon. “We look forward to sharing these findings as part of podium presentations at the upcoming annual meetings for the Retina Society and Euretina Congress in Europe, and hosting a symposium with leading global experts to discuss the mechanism of action and significant opportunity for ANX007 to transform the GA treatment landscape.”